ライフサイエンスコーパス: dominant-negative

1 unctionally null or hypomorphic, while 1 was dominant negative.

2 ufficient hypomorph or neomorph, rather than dominant negative.

3 ase mutations in PKA regulatory subunits are dominant negative.

4 ion, indicating that V679A and R695H are not dominant negatives.

5 y of rapamycin or an adenovirus encoding the dominant negative acting mTOR-mutated protein into the u

6 . elegans genetic complementation assays and dominant negative activities in mammalian systems, resul

7 ce truncated proteins that could either have dominant negative activities or cause loss of function a

8 Pathogenic variants exhibited dominant negative activity and were largely confined to

9 No dominant negative activity of the mutant was observed.

10 The most common mutation, DNMT3A(R882H), has dominant negative activity that reduces DNA methylation

11 evance of such effects (gain of function and dominant-negative activity) in lung adenocarcinoma are u

12 cribed an exon-skipping mechanism for CARD11 dominant-negative activity.

13 turally occurring Ras effectors and acted as dominant-negative affinity reagents that block Ras signa

14 Expression of a dominant-negative allele of MYC, termed OmoMYC, can indu

15 The TP53 mutations we observed are dominant negative and are the mutations most commonly se

16 Using mice expressing dominant negative and constitutively active Ampk in skel

17 r myc-LMX1BWT or myc-LMX1BR246Q, we observed dominant negative and haploinsufficiency effects of the

18 of reactive oxygen species, suggesting both dominant negative and loss-of-function effects of the mu

19 11 encodes an adaptor protein that expresses dominant-negative and gain-of-function variants associat

20 mediated expression of the most potent SARM1 dominant-negative and nerve transection as a model of se

21 R882mut) has been shown to have hypomorphic, dominant-negative, and/or gain-of-function effects on DN

22 Using a dominant-negative AP-1 cell line, we found that both AP-

23 When we blocked ER motility using a dominant negative approach against myosin V, spine synap

24 Using a cardiomyocyte-specific dominant negative approach, we show that blocking AP-1 f

25 s shown by knockdown and overexpression of a dominant-negative Arf6 mutant.

26 The general tendency of dominant negative asymmetry response for ecosystem produ

27 embling those induced by expression of known dominant-negative ATPase-defective forms of VPS4A.

28 sion of Disheveled (Dvl), Frizzled (Fz8), or dominant-negative Axin induced endocytosis.

29 AaVA-1 intracellularly interacts with a dominant negative binder of Beclin-1, known as leucine-r

30 As a result, p97-R155C acts as a dominant negative, blocking protein extraction by a simi

31 n limits MAL glutathionylation and acts as a dominant negative, blocking the interaction of MAL with

32 in Cav1(-/-) MEFs, CAV1-P158 functions as a dominant negative by partially disrupting WT CAV1 traffi

33 we hypothesized that selective expression of dominant-negative C-terminus-truncated human DISC1 (muta

34 st using transient viral (HSV) expression of dominant-negative CaMKII-alpha (K42M) in the hippocampus

35 rate rapidly, axons of mice expressing SARM1 dominant-negative can remain intact for >10 d after tran

36 AV1 was evident, whereas transduction with a dominant negative CAV1 mutated at tyrosine 14 reduced th

37 ed in the disease tissues, whereas that of a dominant-negative CD40 isoform was decreased.

38 OXT-specific expression of dominant-negative Cdc42, which is a key regulator of act

39 hat either CDK5 knockdown or expression of a dominant negative CDK5 results in synergistic induction

40 nt leading process branching by expressing a dominant negative Cdk5.

41 Expression of dominant negative CLOCK (DeltaCLK), which inhibits molec

42 manner: expressing either activated Rac1 or dominant-negative cofilin in the mushroom bodies (MBs) a

43 we report the design and synthesis of cyclic dominant negative competence-stimulating peptide (dnCSP)

44 educing astrocyte gap junction coupling with dominant negative connexin 43 or by disrupting lactate e

45 d ARCaPM prostate cancer cell models using a dominant-negative construct resulted in decreased tumor

46 Finally, expression of a dominant-negative construct that competes with EB3 bindi

47 orms were blocked by overexpressing specific dominant-negative constructs in either presynaptic or po

48 s with only loss-of-function effects (mostly dominant-negative current amplitude reduction) in eight

49 We previously identified Vif mutants with a dominant-negative (D/N) phenotype that interfered with t

50 We previously identified dominant-negative (D/N) Vif variants whose expression in

51 Using a dominant-negative, deacetylase-dead point mutant virus (

52 Wild-Type and dominant-negative-DISC1 (DN-DISC1) mice were injected wi

53 serpins, a hallmark of serpinopathies, with dominant-negative disease mechanisms affecting C1INH pla

54 e an animal model of inducible expression of dominant-negative disrupted in schizophrenia 1 (DN-DISC1

55 nic mice whose endothelial cells expressed a dominant negative (DN) EGFR (inhibits EGFR signaling) ex

56 ard increased fusion through expression of a dominant negative (DN) form of the fission protein [dyna

57 sruption of these channels, by expression of dominant negative (DN) subunits, leads to changes in cir

58 Furthermore, a Rab4a dominant negative (DN) that blocks trafficking at recycl

59 stitutively active (CA) (G12V/G13D/Q61H), or dominant-negative (DN) (S17N)-KRAS and -NRAS, or BRAF-V6

60 A dominant-negative (dn) atypical PKM selectively reversed

61 We found that overexpression of dominant-negative (DN) forms of NSF or knockdown of the

62 PRAS40 knockdown (KD) or PRAS40 dominant-negative (DN) mutant overexpression blocks not

63 CaMKIV signaling in individual neurons using dominant-negative (dn) or constitutively-active (ca) for

64 gE syndrome (AD-HIES) is typically caused by dominant-negative (DN) STAT3 mutations.

65 lateral branching in vitro and expression of dominant negative Drp1 impairs the branching of axons in

66 downregulation with combined expression of a dominant negative dynamin 1 and beta-arrestin 2 knockdow

67 s speculated that NtBRC2A probably confers a dominant negative effect by interfering with the branchi

68 ly reported Ca(2+)-binding cooperativity and dominant negative effect of mutation of the Ca(2+)-bindi

69 sion in gap junction channels, reverting the dominant negative effect of the p.Asp50Asn mutation.

70 trate that patient mutations in TOP2B have a dominant negative effect on enzyme function, resulting i

71 rkin-mediated degradation, but instead had a dominant negative effect on mitochondrial fusion only wh

72 sent B cells and was demonstrated to exert a dominant negative effect on T- and B-cell development in

73 eas the FLCN K508R mutant protein may have a dominant negative effect on the function of wild-type FL

74 pression of Spcdc25 and is consistent with a dominant negative effect on WEE1 action.

75 ts in loss of function while also exerting a dominant negative effect on wild-type CARD11.

76 with the LMX1BR246Q mutation may be due to a dominant negative effect on WT1(-KTS) isoforms that may

77 tp53) tumor suppressor function or exhibit a dominant negative effect over wtp53.

78 ween 677 and 917 amino acids seems to have a dominant negative effect, whereas proteins shorter (486

79 of endogenous alpha1 subunit, analogous to a dominant negative effect.

80 e variants in the DNA-binding domain exert a dominant-negative effect (DNE).

81 DNMT3A(R882mut), shows a requirement of the dominant-negative effect by DNMT3A(R882mut) for leukemog

82 function, including haplo-insufficiency or a dominant-negative effect caused by the assembly of trunc

83 ed fully functional in ndk5 cells elicited a dominant-negative effect in wild-type cells, causing par

84 essential function could be abrogated by the dominant-negative effect of HOXD10 as shown by a genetic

85 Cell transfection studies demonstrated a dominant-negative effect of the p.His257Arg mutation on

86 m(2) (6,6)A levels in 18S rRNA, indicating a dominant-negative effect of this variant on m(2) (6,6)A

87 c overexpression of CPn0678-GFP results in a dominant-negative effect on endocytotic processes in gen

88 unctioning pol II enzyme, thereby inducing a dominant-negative effect on gene transcription.

89 The mutant does not have a dominant-negative effect on native neuronal GABA(A)R exp

90 f E2 approximately Ub and thus a concomitant dominant-negative effect on other E3s in vitro, raising

91 hypotonia and developmental delay through a dominant-negative effect on pol-II-mediated transcriptio

92 This suggests either a dominant-negative effect or haploinsufficiency.

93 mise therapeutic response, due either to the dominant-negative effect over the functional wild-type a

94 a de novo truncation mutation resulting in a dominant-negative effect that is associated with juvenil

95 ing the Sin3-like domain, which could have a dominant-negative effect.

96 .412C>T (p.Arg138Cys) variants resulted in a dominant-negative effect.

97 ing both the addiction to mutant p53 and the dominant-negative effect; and retard tumor growth in xen

98 wild-type or mutant H3.3 alleles and showed dominant negative effects of H3.3R26 and H3.3K27 in modu

99 ressor 1 (NCOR1) was reported to mediate the dominant negative effects of mutated TRalpha1.

100 eins, Su(H)(S269D) and Su(H)(R266H) provoked dominant negative effects upon overexpression.

101 of TP53 not only lead to loss of function or dominant negative effects, but also promotes a gain of f

102 rm mixed tetramers, which in some cases have dominant-negative effects (DNE) that inactivate wild-typ

103 These regulatory components limit the dominant-negative effects of mutant p53 on wild-type p53

104 ivity in TopFlash assay, consistent with its dominant-negative effects on Klp64D-dependent Wg signali

105 EA2-causing mutants may exert dominant-negative effects on the CaV2.1 wild-type subuni

106 aploinsufficiency versus gain-of-function or dominant-negative effects specific to these missense var

107 ate cancers result from gain-of-function and dominant-negative effects toward BET proteins, respectiv

108 variants, which demonstrated potent, graded dominant-negative effects.

109 he multivesicular body (MVB) pathway using a dominant negative ESCRT (endosomal sorting complexes req

110 n embryonic stem cells and by expressing the dominant-negative ETS1 p27 isoform in cord blood hematop

111 AD HIES-causing STAT3 mutant alleles can be dominant-negative even if the encoded protein is produce

112 as determined in cardiac-specific AMPKalpha2 dominant negative expressing mice (AMPK-DN).

113 ected secretion of normal C1INH protein in a dominant-negative fashion by triggering formation of pro

114 stone lysine acetyltransferase activity in a dominant-negative fashion, with concomitant global reduc

115 ld potentially undermine TLR3 signaling in a dominant-negative fashion.

116 ions have previously been found to produce a dominant negative for TRESK, a two-pore-domain K+ channe

117 Here, we show that expression of a dominant negative form of AMPK or inactivation of AMPK a

118 uces a gain of function that gives rise to a dominant negative form of CAV1, defining a new mechanism

119 ese drugs is eliminated in mice expressing a dominant negative form of NR4A and attenuated in mice wi

120 ivity of wild-type RUNX1 and functioned as a dominant negative form of RUNX1, resulting in enhanced s

121 Here, we used a mouse expressing a truncated dominant negative form of the human TCF4 transcription f

122 To address this, we generated an inducible dominant negative form of the IP(3)R (IP(3)R(DN)).

123 The introduction of the dominant-negative form of RAGE lacking RAGE signalling t

124 associated degradation (ERAD) pathway with a dominant-negative form of the ERAD core component, valos

125 ession of luciferase together with Myc and a dominant-negative form of Trp53 revealed that GABAergic

126 Our prior studies have shown that a mutant (dominant-negative) form of a rare but highly penetrant p

127 (siRNA) to Rab5 or Rab7 and cells expressing dominant negative forms of these GTPases, suggesting ent

128 nvestigations using constitutively active or dominant-negative forms of Rab GTPases provided addition

129 rat cortical neurons using overexpression of dominant-negative forms of several transcription factors

130 nant distal hereditary motor neuropathy of a dominant-negative frameshift mutation at the C-terminus

131 ely large effect size conferred by a partial dominant-negative function phenotype.

132 with this finding, FXR overexpression and a dominant-negative FXR mutation reduced and augmented, re

133 (RNA-i) constructs against G-proteins, or a dominant negative G-protein eliminated the increase in G

134 Thus, prostate-specific expression of a dominant-negative G protein-coupled receptor kinase 2 (G

135 in pathologies through loss of function and dominant negative/gain of function effects.

136 Preferential binding to dominant negative (GDP-bound) versus wild-type or consti

137 tudy, we used viral-mediated expression of a dominant-negative GluN1 subunit (HSV-dnGluN1) in VTA neu

138 A catalytically inactive dominant-negative GODZ construct significantly reduced H

139 Finally, dominant-negative GusR variants are validated in cell-ba

140 (+) channel antagonist is able to rescue the dominant-negative heterozygous phenotype.

141 lls could not suppress CD4(+) T cells with a dominant-negative IL-10R.

142 ein (D427ins17) that is loss-of-function and dominant-negative in terms of tyrosine phosphorylation,

143 ation of human myogenic progenitors and that dominant negative inhibition of TCF4 prevents differenti

144 n but not the Rad50 binding domain acts as a dominant negative inhibitor of E2-dependent HPV replicat

145 d glutamate, but not GABA, release acting as dominant negative inhibitor of the functions of this APP

146 One example is CHRFAM7A, a dominant-negative inhibitor of the antiinflammatory alph

147 somes, and that the Stx3-5R mutant acts as a dominant-negative inhibitor.

148 lternative spliced mRNA isoforms that encode dominant-negative inhibitors of the response.

149 This study provides evidence for a conserved dominant-negative inhibitory role of histone K-to-M muta

150 This "functional dominant negative" interaction would produce a more prof

151 ar/social contexts via physical containment, dominant-negative interactions or apoptosis.

152 o because OMPs that assemble slowly can form dominant-negative interactions with the Bam complex.

153 ed by conditional transgenic expression of a dominant negative ion pore mutant of TRPC5 (DNT5).

154 he adjuvant, an adenoviral vector encoding a dominant negative isoform of Src homology region 2 domai

155 The first half acts as dominant-negative isoform suppressing poison cassette ex

156 B knockout or viral-mediated expression of a dominant negative, kinase-dead TrkB mutant.

157 Using dominant-positive (LdSar1:H74L) and dominant-negative (LdSar1:T34N) mutants of LdSar1, we fo

158 We previously identified a dominant negative ligand that antagonizes the TRAIL-depe

159 ted patients and characterized it as being a dominant negative ligand to subvert TRAIL-mediated killi

160 at position R882 have been shown to cause a dominant negative loss of DNMT3A methylation activity, b

161 BQLN2 mutations drive pathogenesis through a dominant-negative loss-of-function mechanism in autophag

162 utations in the gene KCNA2, causing either a dominant-negative loss-of-function or a gain-of-function

163 at the non-binding SGBP-B* protein acts in a dominant negative manner to inhibit growth on xyloglucan

164 reover, the Galphaq T96S mutant may act in a dominant negative manner to promote tumor growth in NKTC

165 genes to identify polypeptides that act in a dominant negative manner, in that they are depleted duri

166 nhibited G-CSF-induced expression of NE in a dominant negative manner.

167 SERPING1 acts upon wildtype (WT) C1INH in a dominant-negative manner and forms intracellular C1INH a

168 e function of the wild-type FEN1 enzyme in a dominant-negative manner and impairs long-patch base exc

169 ne 3 Lys-36 to Met mutation (K36M) acts in a dominant-negative manner to cause global reduction of H3

170 ation, and that the mutated kinase acts in a dominant-negative manner to reduce CaMKIIalpha-WT autoph

171 57A/G58D) , which are considered to act in a dominant-negative manner, resulted in enhanced collapse

172 -43 to mislocalize and aggregate acting in a dominant-negative manner.

173 us encoding beta-arrestin2 mutants acting as dominant-negatives markedly reduces tau-laden neurofibri

174 cted mice expressing the pan-Notch inhibitor dominant negative mastermind-like within mature T cells

175 iated transcription by ectopic expression of dominant-negative mastermind-like (dnMaml) peptide in th

176 erapy displacement of endogenous MCUb with a dominant-negative MCUb transgene (MCUb(W246R/V251E)) in

177 A2, and that the Leu85Pro variant acts via a dominant negative mechanism to reduce, but not eliminate

178 The genetic analysis favors a predominantly dominant-negative mechanism for the action of amino acid

179 urvived to adulthood, suggesting a potential dominant-negative mechanism for the missense variants.

180 caused by DNMT3A(R882mut), thus supporting a dominant-negative mechanism in cells.

181 esize that the fusion protein acts through a dominant-negative mechanism to cause this fatal mitochon

182 Four were suspected to have a dominant-negative mechanism, which correlated with sever

183 actor Xa or thrombin generation, excluding a dominant-negative mechanism.

184 HI) mechanisms, such as gain-of-function and dominant-negative mechanisms, are often characterized by

185 sion via Ca(2+) /NFAT signalling whereas the dominant negative membrane-anchored C-terminal fragment

186 eciprocal activation of Ca(2+) influx by the dominant negative membrane-anchored C-terminal tail frag

187 analysis revealed that 3 of these 6 putative dominant negative missense variants localized to an elec

188 ne receptor alpha (THRA) gene mutations, via dominant negative mode, cause erythroid abnormalities in

189 carrier (MPC) isoforms or expression of the dominant negative mutant MPC1(R97W) resulted in increase

190 Gene transfer of dominant negative mutant of BiP in the lung endothelium

191 olog (Cdc42) because cooverexpression of the dominant negative mutant of Cdc42 [namely, Cdc42-T17N (v

192 Overexpression of a dominant negative mutant of EhRab35 reduced phagocytic c

193 and functional role of omega, we isolated a dominant negative mutant of omega (omega6), which is pre

194 on of the gain-of-function G019S mutation or dominant negative mutant of TRPC6) results in the misloc

195 The dominant negative mutant recombinant SPLUNC1 (p.G22E) sh

196 he tumor-related lncRNA HOTAIR, comprising a dominant negative mutant that was computationally design

197 -Cys (DHHC) zinc finger protein; (ii) a GODZ dominant-negative mutant and an inhibitor of palmitoylat

198 factor 6 (ARF6) small interfering RNA, ARF6 dominant-negative mutant ARF6(T27N), and ARF6 activation

199 By using cell lines stably expressing a dominant-negative mutant form of VPS4, we also show that

200 Expression of dominant-negative mutant HNF-1beta in mIMCD3 cells produ

201 the IkappaB kinase inhibitor BAY11-7085 and dominant-negative mutant IkappaBalphaM inhibited NF-kapp

202 n of PKMzeta in mPFC by expressing a PKMzeta dominant-negative mutant induced depressive-like behavio

203 d stress in OsCAF1B overexpression lines and dominant-negative mutant lines.

204 We fused a dominant-negative mutant of 53BP1, DN1S, to Cas9 nucleas

205 Accordingly, expressing a dominant-negative mutant of GAB1, which reduced its inte

206 Expressing a dominant-negative mutant of NF-YA, a key transcriptional

207 and NF-kappaB, as well as transfection of a dominant-negative mutant of Ras (RasN17), significantly

208 se observations suggest that D477G acts as a dominant-negative mutant of RPE65 that delays chromophor

209 interaction of UL20 with GODZ, using a GODZ dominant-negative mutant or possibly GODZ shRNA, should

210 xpression of the Spc110 C terminus acts as a dominant-negative mutant that titrates endogenous Spc110

211 we demonstrate that the overexpression of a dominant-negative mutant variant of human PROM1 (i.e. mu

212 Overexpression of dominant negative mutants of GRAF1/2, WDR44, and MICAL1

213 In experiments using dominant negative mutants, cdc42 activity was required f

214 Here, we show that dominant-negative mutants of ATL1 in PC-12 cells inhibit

215 Dominant-negative mutants of PAX5 and IKZF1, however, re

216 endosomes are disrupted by the expression of dominant-negative mutants of Rab5 and Rab11.

217 Mice selectively expressing PPARgamma dominant negative mutation in vascular smooth muscle exh

218 correction of both compound heterozygous and dominant negative mutations associated with genetic dise

219 el in which missense PMEL variants represent dominant negative mutations that impair the ability of P

220 yosis is a skin fragility disorder caused by dominant-negative mutations in KRT1 or KRT10.

221 A subset of van der Woude cases is caused by dominant-negative mutations in the epithelial transcript

222 pressed hTACI A181E and mTACI A144E acted as dominant-negative mutations in transfectants, homozygosi

223 Herein, we describe the engineering of the dominant-negative MYC peptide (OmoMYC) linked to a funct

224 role of ssbp1 in retinal development and the dominant-negative nature of the identified human variant

225 omoter activity, whereas the introduction of dominant-negative NRF-1 repressed such activity.

226 HOTAIR-sbid acted as a dominant negative of the endogenous HOTAIR.

227 The remaining mutations are probably weakly dominant negative or their effects are context dependent

228 Overexpression of a PK4 dominant-negative or pharmacological inhibition of PK4 b

229 Transgenic mice expressing a dominant-negative Orai1 mutant (E108Q) increases albumin

230 lencing p300 in myotubes or overexpressing a dominant negative p300 mutant lacking acetyltransferase

231 itor SB202190, and kinase-dead [p38(KD)] and dominant-negative [p38(DN)] forms of p38alpha.

232 ailed to induce dormancy in cells expressing dominant-negative p38alphaMAPK while BMP1 remained activ

233 mice, even in the presence of a conditional dominant negative p53 protein and chronic hypoxia.

234 Ablation of A1-V1 complex with dominant-negative peptides against these domains substan

235 In fact, BipA-H78A confers a dominant negative phenotype in wild-type cells.

236 anges to a highly conserved region, yields a dominant-negative phenotype that causes more severe grow

237 egies mimicking TBK1-DRP1 signaling produced dominant-negative phenotypes reminiscent of human DRP1 i

238 nstrate that this X-linked mutation produces dominant-negative phenotypes, including decreased flying

239 Importantly, dominant-negative physiological and biochemical defects

240 wn-regulation of PKAc1 or stabilisation of a dominant-negative PKAr isoform that does not bind cAMP t

241 However, the isoform specificity of dominant-negative-PKMs to erase LTF is correlated with i

242 t UL20 is palmitoylated by GODZ using a GODZ dominant-negative plasmid.

243 Dominant negative polypeptides can inhibit protein funct

244 The S348A/S409A mutant of LARP6 acts as a dominant negative protein in collagen biosynthesis, whic

245 A mutation in AML patients (R882H) encodes a dominant-negative protein that reduces methyltransferase

246 r allogeneic T cells selectively expressed a dominant negative RA receptor alpha that blunted RA sign

247 defective trafficking in cystinosis, whereas dominant-negative Rab11 or Rab7 impaired LAMP2A traffick

248 more, knockdown of Rab35 and expression of a dominant-negative Rab35 mutant both inhibited histamine-

249 l blockade of both pathways by Atg5(-/-) and dominant-negative rab5, ER cholesterol fails to increase

250 Dominant-negative RAB7A expression resulted in similar d

251 Similar effects were observed when a dominant-negative Rab9 mutant (Rab9-GDP) was employed.

252 ng Rac1 signaling by RNAi, expression of the dominant-negative Rac1 (Rac1 DN), or the specific Rac1 i

253 Conversely, dominant-negative Rac1 or activated cofilin MB expressio

254 t the heterozygous mutations in L-ORD show a dominant negative, rather than a haploinsufficient, dise

255 ed in the ability to bind FADD functioned as dominant negative receptors (DNRs), preventing FasL-indu

256 at the truncated form of GGA1 behaviors as a dominant-negative regulator for the cell surface export

257 Rather than being dominant-negative regulators, Tcf1 short isoforms are ad

258 nnel subfamily E (KCNE) subunit 4, acts as a dominant negative regulatory subunit to both enhance ina

259 e fusion protein encoded by CBFB-MYH11, is a dominant negative repressor of RUNX1.

260 l transition and, contrary to their proposed dominant-negative role, did not interfere with the expre

261 fibroblasts from a heterozygous carrier of a dominant-negative SERPING1 gene variant, but the conditi

262 astrocytes by virally driven expression of a dominant-negative SNARE protein (dnSNARE) increased baro

263 Conversely, the dominant-negative sob3-6 mutant has long petioles, a phe

264 inally, overexpression of wild type, but not dominant negative SPHK2, suppresses CAMP production in b

265 Transfection of a dominant-negative STAT3 mutant, but not of STAT1, abroga

266 Individuals with dominant-negative STAT3 mutations (STAT3(mut) ) or a los

267 Accordingly, patients with dominant-negative STAT3 mutations show no tolerance deve

268 using a novel hypoxia-dependent, reversible dominant-negative strategy to regulate autophagy at the

269 Using a SUN dominant-negative strategy, we demonstrate that LINC com

270 nhibitor compound C or adenovirus expressing dominant-negative subunits of AMPK increased cue-induced

271 We report 1) that hERG1a dominant-negative subunits suppress hERG1b currents (and

272 This enables IRE1beta to act as a dominant-negative suppressor of IRE1alpha and affect how

273 zNep, phenocopies expression of an inducible dominant negative TBX2.

274 of the small GTPase TC21 or expression of a dominant-negative TC21 reduced S6 phosphorylation but no

275 expression) or loss-of-function experiments (dominant negative TCF4).

276 Here, we describe a designed dominant negative termed A-ZIP53 that has a glutamic aci

277 ed backtracking sites in human cells using a dominant-negative TFIIS (TFIIS(DN)) that inhibits RNA cl

278 Male and female dominant-negative TGF-beta receptor II (dnTGF-betaRII) (

279 We, therefore, developed SARM1 dominant-negatives that potently block AxD in cellular m

280 By expression of a dominant-negative TNF peptide via lentiviral vector inje

281 that the engineered monomer functioned as a dominant negative to inhibit TGF-beta signaling with a K

282 Furthermore, a dominant-negative Torsin induces chromosome segregation

283 ated, either by HPV16 E6, by expression of a dominant negative TP53 minigene, or by TP53 depletion.

284 in MDCK monolayers led to the proposal of a dominant-negative trafficking mechanism to explain AE1-a

285 Using mice expressing a dominant negative TRalpha1 mutant (TRalpha1PV; Thra1 (PV

286 ere engineered to express wild-type TRPC6, a dominant negative TRPC6 mutation, or either of two disea

287 raine because it leads to the formation of a dominant negative truncated TRESK fragment.

288 suppressed vesicle traffic similarly to the dominant-negative truncated protein SYP121(DeltaC), whic

289 members, resulting in expression of the TP53 dominant negative truncations DeltaNTrp63 and DeltaNTrp7

290 ds to inhibit unc-9-based gap junctions with dominant-negative unc-1 transgenes.

291 Macropinocytosis was blocked by dominant-negative vacuolar protein sorting 4 (Vps4), ind

292 of the suppressing DNAs encoded a truncated dominant-negative variant of the 26S proteasome subunit,

293 Of note, the expression of c-Fos dominant-negative variants capable of blocking its lipid

294 The deletion of GEF-H1 or dominant-negative variants of GEF-H1 prevent activation

295 Analyses of the effects of overexpression of dominant-negative VAV3 constructs or shRNA-mediated down

296 tion of TPL activity induced by expressing a dominant negative version of TPL (tpl-1) in phloem compa

297 Here, we show that overexpression of a dominant-negative version of DA1 enhances leaf size in a

298 The mutant proteins are loss-of-function and dominant-negative when tested following overproduction i

299 n of the Klp64D cargo domain also results in dominant-negative wing notching.

300 interaction in neurons with PAT1 siRNA or a dominant-negative ZBP1 construct diminished localization